Analysis Article • Jun 19
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedJul 03, 2026
DataAggregated Company Financials
Companies12
- 7D5.1%
- 3M-5.6%
- 1Y28.5%
- YTDn/a
The Clinical Research and Equipment industry is up 5.1% in the last week, with WuXi Biologics (Cayman) up 8.3%. Meanwhile, InSilico Medicine Cayman TopCo actually underperformed within the industry, shrinking 16% in the last week. This takes the industry's 12 month performance to a gain of 28%. Earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 03 Jul 2026 | HK$320.2b | HK$48.5b | HK$1.2b | 31.3x | 273.6x | 6.6x |
| Sun, 31 May 2026 | HK$310.8b | HK$48.6b | HK$1.2b | 25.5x | 258.4x | 6.4x |
| Tue, 28 Apr 2026 | HK$330.6b | HK$48.3b | HK$1.1b | 31.4x | 291x | 6.9x |
| Thu, 26 Mar 2026 | HK$318.7b | HK$47.5b | HK$2.9b | 25.4x | 111x | 6.7x |
| Sat, 21 Feb 2026 | HK$383.8b | HK$43.5b | HK$6.1b | 45x | 63.1x | 8.8x |
| Mon, 19 Jan 2026 | HK$387.0b | HK$43.1b | HK$6.0b | 47.5x | 64.4x | 9x |
| Wed, 17 Dec 2025 | HK$302.4b | HK$42.2b | HK$6.3b | 45.8x | 48.2x | 7.2x |
| Fri, 14 Nov 2025 | HK$333.9b | HK$41.9b | HK$6.2b | 49.1x | 53.6x | 8x |
| Sun, 12 Oct 2025 | HK$348.7b | HK$41.8b | HK$6.2b | 48.5x | 56.2x | 8.3x |
| Tue, 09 Sep 2025 | HK$347.2b | HK$41.9b | HK$6.2b | 48.5x | 55.9x | 8.3x |
| Thu, 07 Aug 2025 | HK$286.2b | HK$37.2b | HK$2.7b | 60.3x | 104.6x | 7.7x |
| Sat, 05 Jul 2025 | HK$231.5b | HK$37.3b | HK$2.7b | 46x | 84.3x | 6.2x |
| Mon, 02 Jun 2025 | HK$204.4b | HK$36.1b | HK$2.6b | 27.8x | 78.7x | 5.7x |
| Wed, 30 Apr 2025 | HK$191.0b | HK$35.5b | HK$2.5b | 26.1x | 75.2x | 5.4x |
| Fri, 28 Mar 2025 | HK$211.8b | HK$35.5b | HK$1.3b | 38.2x | 166.5x | 6x |
| Sun, 23 Feb 2025 | HK$218.3b | HK$35.8b | -HK$1,056,622,045.45 | 61.1x | -206.6x | 6.1x |
| Tue, 21 Jan 2025 | HK$156.9b | HK$35.7b | -HK$1,061,042,410.64 | 57.3x | -147.9x | 4.4x |
| Thu, 19 Dec 2024 | HK$159.5b | HK$35.7b | -HK$1,058,167,722.33 | 59.1x | -150.7x | 4.5x |
| Sat, 16 Nov 2024 | HK$141.7b | HK$36.0b | -HK$1,057,889,741.42 | 43.5x | -134x | 3.9x |
| Mon, 14 Oct 2024 | HK$168.2b | HK$35.9b | -HK$654,984,778.47 | 30.3x | -256.8x | 4.7x |
| Wed, 11 Sep 2024 | HK$146.3b | HK$35.8b | -HK$662,121,884.72 | 23.9x | -221x | 4.1x |
| Fri, 09 Aug 2024 | HK$98.6b | HK$33.7b | HK$3.1b | 17.8x | 31.6x | 2.9x |
| Sun, 07 Jul 2024 | HK$88.3b | HK$33.4b | HK$3.1b | 19.4x | 28.7x | 2.6x |
| Tue, 04 Jun 2024 | HK$87.5b | HK$33.5b | HK$3.1b | 25.6x | 28.3x | 2.6x |
| Thu, 02 May 2024 | HK$111.9b | HK$33.5b | HK$3.1b | 29.4x | 36.2x | 3.3x |
| Sat, 30 Mar 2024 | HK$116.9b | HK$33.6b | HK$3.1b | 34.4x | 37.6x | 3.5x |
| Mon, 26 Feb 2024 | HK$134.5b | HK$32.3b | HK$3.0b | 54.2x | 45.2x | 4.2x |
| Wed, 24 Jan 2024 | HK$196.1b | HK$32.4b | HK$3.0b | 86.8x | 65.6x | 6.1x |
| Fri, 22 Dec 2023 | HK$206.9b | HK$32.4b | HK$3.0b | 89x | 68.9x | 6.4x |
| Sun, 19 Nov 2023 | HK$291.8b | HK$32.1b | HK$3.0b | 87.4x | 98.7x | 9.1x |
| Tue, 17 Oct 2023 | HK$262.3b | HK$30.1b | HK$2.7b | 46.9x | 98.2x | 8.7x |
| Thu, 14 Sep 2023 | HK$226.2b | HK$30.2b | HK$2.7b | 39.9x | 84.1x | 7.5x |
| Sat, 12 Aug 2023 | HK$235.5b | HK$28.3b | HK$2.7b | 23.7x | 87x | 8.3x |
| Mon, 10 Jul 2023 | HK$203.8b | HK$28.4b | HK$2.7b | 20.6x | 75.1x | 7.2x |
Price to Earnings Ratio
75.1x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 274x which is higher than its 3-year average PE of 26.3x.
- The 3-year average PS ratio of 6.0x is lower than the industry's current PS ratio of 6.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 24% per year over the last three years.
- Meanwhile revenues for these companies have grown 19% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | -1.89% | |
| Healthcare | 7.17% | |
| Life Sciences | 5.10% | |
| Clinical Research and Equipment | 5.10% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$37.56 | 13.7% +HK$18.6b | 43.4% | PE27.2x | |
| 2268 WuXi XDC Cayman | HK$61.70 | 12.2% +HK$8.4b | 37.7% | PE45.4x | |
| 2228 XtalPi Holdings | HK$7.90 | 17.0% +HK$4.9b | 45.5% | PE237.6x | |
| 1548 Genscript Biotech | HK$13.61 | 15.4% +HK$4.0b | -9.9% | PS4x | |
| 2576 Zhejiang Taimei Medical Technology | HK$7.00 | 7.7% +HK$281.8m | 107.1% | PS6.7x |